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ABSTRACT 
 Systemic sclerosis (SSc) is a clinically heterogenous chronic fibrotic 
disease which affects skin and internal organs. While the pathogenesis of SSc 
remains unknown, the hallmark of both localized and diffuse SSc in the skin is 
the replacement of normal dermal architecture with excessive deposition of 
collagen and other connective tissue macromolecules. Progressive replacement 
of tissue architecture by collagen-rich extracellular matrix (ECM) results in 
functional impairment of affected organs. Fibrotic damage to these affected 
organs accounts for much of the morbidity and mortality concomitant with SSc, 
particularly in the lungs.  
Myofibroblasts are the primary ECM-secreting cells during wound healing 
and fibrosis. Myocardin-related transcription factor A (MRTF-A), is an important 
regulator of myofibroblast differentiation, depending on serum response factor 
(SRF) for smooth muscle actin (SMA) and Sp1 in the regulation of collagen gene 
expression. MRTF-A continually shuttles between the nucleus and cytoplasm in 
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unstimulated cells. Signals of stress, mechanical force, and migration control 
MRTF-A movement by a mechanism in which Rho-activated cytoskeletal actin 
polymerization induces its relocation from the cytoplasm to the nucleus. The 
major hypothesis in this thesis is that MRTF-A is dysregulated (impairment of a 
physiological regulatory mechanisms) and/or activated in SSc patients in part 
through transforming growth factor beta (TGF-β). To test this hypothesis, 
immunohistochemistry using MRTF-A antibodies was performed on SSc patient 
skin lesions and healthy control skin. Staining was observed in the epidermis, 
epidermal structures, vasculature and dermis of SSc and healthy control skin. In 
the epidermal layer of patients with SSc, there was significantly more nuclear 
localization of MRTF-A then in normal controls. Prominent staining is also 
present in endothelial, perivascular and some perivascular inflammatory cells of 
SSc patients. Perivascular staining was not seen in healthy controls. 
Interestingly, there was some accumulation of nuclear MRTF-A in areas typical of 
myofibroblasts in SSc skin, but this staining is not as striking as vascular staining.   
TGF-β activates MRTF-A in a cell-specific manner. As SSc typically begins 
within the skin, human dermal fibroblasts (HDF) were grown in culture. HDFs 
synthesize and secrete collagen to a greater extent when compared to human 
lung fibroblasts (IMR90 cells). Treatment with TGF-β enhances cytoplasmic 
localization of MRTF-A at 4-8 hours in HDFs and prolongs nuclear localization.   
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Transgenic mouse lung cells were isolated from an MRTF-A loss-of-
function mouse carrying the 3.6 kb proximal promoter of the rat COL1A1 gene 
driving topaz green fluorescent protein (GFP) (pOB3.6COLGFPtpz). Since 
angiotensin II (ANG II) may enhance TGF-β response or collagen transcription 
directly, wild type (WT) and MRTF-A knockout (KO) cells were treated with ANG 
II and TGF-β. Quantification of collagen transcription by GFP fluorescence and 
protein synthesis by Western and secretion by Sircol analysis revealed collagen 
gene expression is consistently lower in KO fibroblasts compared to WT. Total 
percentage of fluorescent KO cells were consistently lower in comparison to WT 
cells as well. KO cells do not respond to TGF-β or ANG II treatment, whereas 
TGF-β increased collagen gene expression by WT cells, but not KO cells. 
Furthermore, treatment with ANG II did not up-regulate transcription in WT 
mouse lung fibroblasts. However, TGF-β receptor kinase 1 (TβR-1) inhibitor 
SB431542 attenuated collagen transcription in both WT and KO fibroblasts 
regardless of treatment suggesting that the receptor is active with or without 
MRTF-A possibly with an endogenous ligand produced by these cells. The 
activation of MRTF-A is an important protein regulating collagen synthesis and 
may potentially serve as a therapeutic target in future treatments of fibrotic 
disease such as SSc.  
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I. Introduction  
Wound Healing and Remodeling 
Following acute tissue injury, repair and remodeling processes occur 
which return the injured tissue to the pre-injured state. There are three 
overlapping stages, inflammation, proliferation, and remodeling, that involve 
many different biochemical processes including chemotaxis, cell division, 
extracellular matrix (ECM) synthesis, neovascularization, and scar tissue 
formation or remodeling (Enoch 2005).  
During the inflammatory phase, hemostasis occurs and an acute 
inflammatory infiltrate follows. Cytokines and growth factors, such as 
transforming growth factor (TGF)-β are released by platelets and contribute to 
the proliferation and recruitment of inflammatory cells (neutrophils, 
monocytes/macrophages, and lymphocytes) to the injury site (Czubryt 2012). 
The acute inflammatory response typically lasts between 24 to 48 hours (Clark 
1996). Hemostasis allows for the formation of a fibrin clot and platelet adherence. 
This occurs through vasoconstriction (vascular spasm) of the injured site to 
reduce blood flow and attenuate blood loss (Boon 1993). Platelet plug formation 
follows, activated by the release of von Willebrand factor, and is held in place by 
fibrin. Coagulation occurs upon the formation of the fibrin mesh (Clemetson 
2012; Szántó 2012).  
The proliferative phase is characterized by fibroplasia, collagen 
deposition, granulation, contraction, epithelialization and angiogenesis to restore 
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tissue perfusion (Kao 2011). The ECM proteins fibrin, fibronectin and collagen 
contribute to the structural integrity of the ECM during repair. Initially fibroblasts 
migrate across the wound through the utilization of the fibrin cross-linking fibers, 
subsequently adhering to fibronectin. Fibroblasts then deposit ground substance 
and collagen into the wound bed (Jacob 2012). Formation of the permeable 
epithelium covers the wound surface with concomitant growth of granulation 
tissue to fill the wound space. The formation of granulation tissue includes the 
proliferation and activation of fibroblasts, deposition of collagens and extracellular 
matrices, and angiogenesis (Midwood 2004).  
The final phase of tissue repair is extracellular matrix (ECM) remodeling, 
wound contraction and scar maturation. Matricellular proteins act temporally and 
locally to trigger specific activities with the wound as the architecture is 
remodeled. Such proteins include galectins, osteopontin, SPARC (secreted 
protein acidic and rich in cysteine), thrombospondins, vitronectin, and tenascins 
(Bornstein 2002; Chiquet-Ehrismann 2003). Following injury and normal healing, 
fibroblasts are activated to proliferate, produce ECM and differentiate into 
myofibroblasts that undergo apoptosis during resolution (Greenhalgh 1998). If 
progression to fibrosis occurs, myofibroblasts continue to proliferate and 
generate excess amounts of ECM. In most chronic fibrotic conditions isolated 
primary fibroblasts sustain their activated phenotype (Bringardner 2008). 
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Scleroderma  
Prevalence and Treatment 
Systemic sclerosis (SSc) is a clinically heterogenous chronic fibrotic 
disease which affects skin and internal organs with additional characteristics of 
small-vessel vasculopathy and evidence of immune dysregulation with 
autoantibody production (Bellando-Randone 2012). Recent estimates indicate a 
prevalence of 276 cases per million adults with an annual incidence of 19.3 new 
cases per million adults diagnosed per year and an approximate median survival 
rate of 11 years in its diffuse form. Women are more at risk than men with a 
4.6:1.0 female-to-male ratio (Mayes 2003). 
Scleroderma is commonly classified into two subsets based on the pattern 
of skin involvement: limited and diffuse. The limited form has less extensive 
involvement of the internal organs whereas the diffuse form has rapid 
widespread internal organ involvement resulting in disability and death within 
several years (Assassi 2009). Whereas scleroderma renal crisis was the main 
cause of SSc-associated deaths in the 1970s, as of 2002, deaths due to renal 
crisis has decreased from 42% to 6%. This is in contrast to the increased 
proportion of patients with SSc who died of pulmonary fibrosis (PF); from 6% to 
33% (Steen 2007). SSc occurs more frequently in families (1.6%) than in the 
general population (0.026%), an approximately 15-fold higher risk for SSc for 
siblings and an approximately 13-fold greater risk for first-degree relatives 
(Maurer 2011). 
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For patients with SSc, progressive replacement of tissue architecture by 
collagen-rich ECM results in functional impairment of affected organs. The 
fibrotic process is most prominent in the skin, lungs, gastrointestinal tract, heart, 
tendons and ligaments, and endocrine glands; widespread perivascular fibrosis 
also occurs. Fibrotic damage to these affected organs accounts for much of the 
morbidity and mortality concomitant with SSc (Bellando-Randone 2012). Besides 
fatigue, which is frequently among the chief complaints of patients, approximately 
80% of patients suffer from gastrointestinal disturbances. Skin fibrosis may lead 
to joint contractures and compromised mobility, and may affect the facial 
appearance with hypomimic features and microstomia (Maurer 2011). Physical 
activity may be further impaired due to lung and cardiac involvement with 
approximately 50% of patients experiencing dyspnea (Maurer 2011). Treatments 
for diffuse SSc include: 1) vasodilators (calcium channel blockers, angiotensin-
converting enzyme inhibitors, and prostaglandins), 2) immunosuppressant drugs 
and 3) antifibrotic agents (Leighton 2001; Sapadin AN 2002). Only inhibitors of 
angiotensin-converting-enzyme (ACE) have demonstrated efficacy in treatment 
of scleroderma renal crisis (Bussone 2011). Localized treatments include 
corticosteroids, vitamin D analogues, UV-A, and methotrexate (Sapadin AN 
2002). To date, no treatments have been proved effective in decelerating the 
advancement of fibrosis in patients with diffuse SSc when evaluated via the 
Rodnan skin score (Allanore 2006). 
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The pathogenesis of SSc is complex and involves abnormalities in 
fibroblasts, endothelial cells and immune cells. Such alterations frequently result 
in severe and progressive fibrosis, prevalent vascular and microvascular disease, 
and cellular and humoral immunologic abnormalities, which include the 
production of autoantibodies, cytokines, chemokines and growth factors 
(Highland 2005). SSc interstitial lung disease arises from abnormal interactions 
among endothelial cells, lymphocytes, monocytes and fibroblasts and are 
presumed to lead to excess ECM production by fibroblasts in the setting of tissue 
hypoxia and vascular hyperreactivity (Solomon 2013). In a postmortem study of 
SSc lung tissue, two major types of cellular abnormalities were seen in the early 
active stages of SSc lung fibrosis; one was the induction of a substantial number 
of interstitial smooth muscle α-actin-positive myofibroblasts and the other was 
excessive development of irregularly shaped alveolar capillaries (neovascularity) 
with an increased quantity of microvascular endothelial cells. However, as 
fibrosis evolves to end-stage lung disease, there is a decline in myofibroblast and 
capillary endothelial cell populations (Beon 2004). The pathogenesis of 
pulmonary fibrosis is classically characterized by abnormalities of alveolar 
structure accompanied by myofibroblast accumulation and collagen deposition in 
the ECM, with resultant lung scarring and gas exchange inhibition (Selman 
2001).  
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Myofibroblasts are central to wound healing and fibrosis 
Function 
Myofibroblasts are a differentiated form of fibroblasts with characteristics 
resembling those of smooth muscle cells and fibroblasts. Activation of 
myofibroblasts is a key event in both normal and pathological fibrogenesis. 
Myofibroblasts are the primary extracellular matrix (ECM)-secreting cells during 
wound healing and fibrosis, and are chiefly responsible for the contractility of 
maturing scar tissue (Hinz 2007). Myofibroblasts disappear in normal scars, but 
persist in hypertrophic scars and in fibrotic lesions of many organs. Tissue 
fibrosis evolving from compromised tissue remodeling post injury is 
characterized by myofibroblast accumulation (Dvorak 1986). In vivo studies 
show a majority of collagen gene expression in bleomycin-induced pulmonary 
fibrosis may be attributed to myofibroblasts and extrapulmonary bone marrow-
derived cells (Phan 1991; Hashimoto 2004). Depending on the type of tissue in 
need of repair, myofibroblast precursor cells are recruited from varying sources; 
the most common being locally residing fibroblasts. Other mesenchymal 
progenitors likely include; 1) pericytes and smooth muscle cells (SMCs) from the 
vasculature, 2) bone marrow-derived circulating fibrocytes, 3) trans-
differentiated fibroblasts from epithelial-mesenchymal transition (EMT) or 4) 
endothelial-to-mesenchymal transition (EndMT)  (Andersson-Sjöland 2008; 
Ghosh 2012; Lama, 2006; Willis, 2006). 
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 The hallmark characteristic of a myofibroblast is the simultaneous 
expression of type I collagen and α-SMA (smooth muscle actin) stress fibers 
and a non-muscle myosin contractile apparatus (Hinz 2007). This specialized 
machinery uses adenosine triphosphate (ATP) hydrolysis to transmit mechanical 
force from inside the cell to the matrix (Ehrlich 2006). At least three local events 
correlate to generate α-SMA-positive differentiated myofibroblasts: 1) 
accumulation of biologically active transforming growth factor (TGF) β-1, 2) the 
presence of specialized ECM proteins like the ED-A splice variant of fibronectin, 
and 3) high extracellular stress, arising from the mechanical properties of the 
ECM and cell remodeling activity (Hinz 2007). Contracture, the perpetual 
shortening and compacting of the ECM network, is then stabilized by additional 
ECM synthesis and deposition and this cycle renews until injury has been 
resolved. 
 A difference between normal and pathological myofibroblasts relates to 
their capability to sustain their dysregulated phenotype. Epigenetic modifications 
may provide a molecular basis for perpetuated fibroblast activation and 
fibrogenesis. For example, hyper-methylation of RASAL1, which encodes a Ras 
oncogene inhibitor, is associated with the perpetuation of fibroblast activation 
and fibrogenesis (Bechtel 2010). Activation of fibroblasts after injury are 
suppressed by demethylating agents yet attenuated if the hyper-methylation of 
RASAL1 was reversed. Studies with Ras inhibitors and DNA methyltransferase-
deficient mice (Dnmt-/-) confirmed that Rasal1 silencing and the resulting 
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increase in Ras activity promote activation of fibroblasts (Wynn 2010). Whereas 
reversible fibroblast activation (typical of physiological repair) is associated with 
reversible RASAL1 suppression without its hypermethylation, sustained 
fibroblast activation is associated with irreversible RASAL1 expression due to 
hypermethylation of the RASAL1 promoter. This suggests that hypermethylation 
perpetuates fibroblast activation and ultimately fibrogenesis by increased 
intrinsic proliferative activity, α-SMA expression and type I collagen expression 
of fibrotic fibroblasts via Ras hyperactivity (Bechtel 2010). 
TGF-β signaling 
The TGF-β isoforms (TGF-β1, TGF-β2 and TGF-β3) are synthesized as 
latent homodimeric proproteins (proTGF-β) complexed with latent TGF-β binding 
proteins (LTBP-1, -3, and -4). Early in the assembly, disulfide linkages are 
formed between cysteine residues of latent TGF-β via LTBP and its propeptide 
latency-associated peptide (LAP) (Leask 2004). The TGF-β LAP isoforms, found 
primarily in the ECM, function as inhibitors via their noncovalent, high-affinity 
association with TGF-β, rendering latent TGF-β incapable of binding to its 
receptors. The 75 kDa proTGF-β is extracellularly cleaved at the carboxyl-
terminal proregion, to which LTBP is bound, to form the mature 24 kDa TGF-β 
protein (Annes 2003). Activators of TGF-β are proteins associated with the 
wound healing response. For example, the activator throbospondin-1 (TSP-1) 
promotes angiogenesis, reconstruction of the matrix, and modulates cellular 
adhesion (Frazier 1991). Another activator, the integrin αvβ6, is typically 
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expressed at low levels in only epithelia, yet induced during inflammation and 
wound healing (Miller 2001). Finally, the plasmin proteases MMP-2 and MMP-9 
promote matrix degradation as well as TGF-β activation (Sato 1989). Thus, 
activation occurs in response to the induction of agents during the wound healing 
response. TGF-β is rapidly induced upon cutaneous injury, attracting neutrophils, 
macrophages and fibroblasts, which subsequently release more TGF-β (Kane 
1991). 
TGF-β has been implicated as a “master switch” in the induction of fibrosis 
in many organs, including the lung, and has been shown to be important in the 
activation of myofibroblasts (Sime 2001). TGF-β plays an important role in 
myofibroblast differentiation during wound healing and in pathologic fibrogenesis 
by α-SMA expression. TGF-β induces α-SMA protein and mRNA expression in 
growing and quiescent cultured fibroblasts (Desmoulière 1993). TGF-β binds a 
type of transmembrane serine/threonine kinase receptors. Only 5 type II 
receptors and 7 type I receptors are recognized in humans, yet there are 29 
known ligands. Type I receptors have a characteristic Gly-Ser (GS) sequence 
upstream of the kinase domain (Rik 2003). Without ligand-binding, they exist as 
homodimers at the cell surface. Ligand binding to either homomeric receptor 
dimer is not sufficient to trigger signaling. By contrast, activation of the type I 
receptor kinase, and resultant signaling, necessitates phosphorylation of its GS 
domain by the type II receptor in the heteromeric complex (Derynck 1997; 
Massagué 2000). Although ligand binding to type II receptor dimers may bring 
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cytoplasmic-domain autophosphorylation, type II receptor signaling has yet to be 
reported in the absence of type I receptors (Rik 2003). Activation of RhoA and its 
effector kinase p160ROCK, as well as Cdc24, p38 MAPK and SMAD signaling 
have been associated in TGF-β-induced stress-fiber formation and EMT (Bakin 
2002; Bhowmick 2001; Edlund 2002; Shen 2001; Yu 2002). ROCK, also a 
required component for contraction and force generation, has been implicated a 
potential therapeutic target for PF, as it has been demonstrated to be a necessity 
in a feed-forward mechanotransduction circuit connecting tissue stiffness with 
fibrosis (Sheppard 2013). In recent studies, the Rho GTPase Rac1 has been 
shown to be required for myofibroblast differentiation and activity. Inhibition of the 
Rac1 reverses the phenotype of fibrotic fibroblasts isolated from the skin of SSc 
patients (Shi-wen 2009). In addition, normal wound repair and dermal 
homeostasis requires expression of Rac1 by dermal fibroblasts, as Rac1 
knockout fibroblasts show significant inhibition in adhesion, spreading, and 
bleomycin-induced fibrosis (Liu 2008). 
Vasoconstrictors Endothelin and Angiotensin 
A number of mechanisms by which TGF-β can be increased have been 
identified. Among them are vasoconstrictors endothelin-1 (ET-1) and angiotensin 
II (ANG II) (Wynn 2007). Endothelins are a family of 21 amino-acid peptides, 
produced by vascular endothelial cells. They not only play an important role in 
vasoconstriction, but also stimulate SMC proliferation. ET-1 is a mediator of 
fibrosis and is overexpressed in plasma as well as dermal fibroblasts cultured 
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from SSc patients (Shojaa 2012). Increase in the plasma levels of ET-1 can 
instigate significant vascular damage, fibrosis, and skin thickening in SSc 
patients. ET-1 is mitogenic for a number of cell types, can modify ECM 
metabolism, promote contractile ability of normal dermal fibroblasts, and 
participates in wound healing and scar formation. ET-1 has also been shown to 
induce myofibroblast formation (Dhaun 2009).  
The vasoconstrictor angiotensin II (ANG II) has emerged as a key 
mediator of sclerosis in hypertensive models because of its pleiotropic effects on 
SMCs, inflammatory cells and fibroblasts (Kahan 2009).  ANG II, a 452–amino 
acid protein, is an oligopeptide produced by two enzymatic cleavages of the 
zymogen angiotensinogen in the renin-angiotensin system (RAS), and plays a 
role in controlling the growth and remodeling of vascular SMCs, regulating renal 
salt and water metabolism and central nervous system mechanisms (Harrison-
Bernard 2009). In the circulating RAS, if the perfusion of the juxtaglomerular 
apparatus in the kidney's macula densa decreases, then the juxtaglomerular cells 
release the enzyme renin, which catalyzes the cleavage of the angiotensinogen 
to produce Angiotensin I (ANG I), which is subsequently converted into ANG II by 
angiotensin-converting-enzyme (ACE) in the lungs (Guiducci 2006).  
 In vitro data indicate that ANG II increases synthesis and decreases 
degradation of pathological ECM components. ANG II exerts its functions 
through two G protein-coupled receptors, type 1 (AT1R) and type 2 (AT2R) 
(Higuchi  2007). Activation of the AT1R receptors is predominantly coupled with 
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GQ/11, and signal through several plasma membrane effector systems. These 
include phospholipases A2, C, D, inositol phosphates, adenylyl cyclase, calcium 
channels, and various serine/threonine and tyrosine kinases to trigger cellular 
response (de Gasparo 2000).  
ANG II and TGF-β1 are, respectively, able to activate ECM production and 
trigger a potent profibrotic response on direct stimulation of SMCs (Wolf 
1998). The intracellular mediators of TGF-β1 signaling are the SMADs 2 and 3, 
which are phosphorylated upon receptor activation and form a heterotrimeric 
complex with Smad4. This complex translocates to the nucleus and mediates a 
majority of the profibrotic transcriptional activation (Sorescu 2006). It is likely that 
Smad3 plays a role in transcription, as it has a DNA-binding and transactivation 
domain. Inhibition of the ANG II blockade suppresses TGF-β, regardless whether 
the therapeutic agent is an ACE inhibitor or an AT1R antagonist (Noble 1997). 
While acute ANG II directly activates transcription of collagens and fibronectin, 
enduring profibrotic effects of ANG II are facilitated by paracrine release of TGF-
β1, which is potently and rapidly upregulated after ANG II stimulation (Border 
1998). 
Myocardin Family 
Myocardin and the myocardin-related transcriptions factors (MRTFs) 
MRTF-A and MRTF-B, the major members of the Myocardin family, share 
common motifs which include an N-terminal MRTF homology domain with RPEL 
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motifs, basic and glutamine-rich regions, an SAP domain and a leucine-zipper 
region (Selvaraj; D.-Z. Wang 2002). Whereas myocardin expression is limited to 
nucleus of cardiac and smooth muscle cell types, multiple cell lineages express 
MRTF-A and MRTF-B in both the cytoplasm and nucleus, including 
undifferentiated embryonic stem cells and fibroblasts (Du 2004). MRTF-A (also 
called MKL1/MAL/BSAC) and MRTF-B (also called MAL16/MKL2) are 
ubiquitously expressed proteins which accumulate in the nucleus in response to 
changes in actin dynamics. The human MRTF-A gene is located at chromosome 
22q13.2 (Parmacek 2010). MRTF-A was first recognized by sequencing of a 
t(1;22)(p13.3;q13.3) translocation event in patients diagnosed with acute 
megakaryocytic leukemia (AML-M7) (Baruchel 1991). Such a translocation 
results in a fusion protein with the human protein One-Twenty-Two (OTT), which 
was later shown to increase transcription of CArG (CC(A/T)6GG) box-containing 
genes in an SRF-dependent manner (Sawada 2008). 
MRTF-A continually shuttles between the nucleus and cytoplasm in 
unstimulated cells. Signals of stress, mechanical force, and migration control 
MRTF-A movement by a mechanism in which Rho-activated cytoskeletal actin 
polymerization induces its relocation from the cytoplasm to the nucleus (Miralles 
2003). Binding of unpolymerised actin (G-actin) to the MRTF N-terminus 
hampers MRTF activity by inhibiting their nuclear accumulation and suppressing 
formation of the MRTF-SRF complex and subsequent transcriptional activation 
(McGee 2011). The MRTF regulatory domain contains three copies of the RPEL 
14 
 
motif. Structure-directed functional studies show that genuine MRTF-A regulation 
necessitates that each of the three RPEL motifs be competent to G-actin binding 
in the N-terminal regulatory domain (Mouilleron 2008). Upon activation of Rho 
proteins, F-actin filament polymerization depletes G-actin availability to bind the 
RPEL domain, leading to exposure of the nuclear localization sequences (NLS) 
and subsequent MRTF-A nuclear translocation (Sebe 2010). Together, these 
results show that actin associates with MRTF-A via the RPEL motifs and that 
Rho-actin signaling leads to dissociation of this complex. G-actin has also been 
shown to interact with nuclear MRTFs, aiding to dampen interactions with SRF 
and facilitate nuclear export. Additionally, as it is ubiquitously expressed, MRTF-
A has retained the SMC contractile gene apparatus expression in non-smooth 
muscle cells such as myoepithelial cells (Li 2006). Furthermore, cell-specific 
expression of actin-binding proteins such as striated muscle activator of Rho 
signaling (STARS) has been shown to activate RhoA and SRF activity via 
competition with MRTFs to bind G-actin (Selvaraj 2003). MRTF-A has also been 
illustrated to be an important inducer of EMT, as seen in the de-differentiation of 
kidney tubular epithelial cells into myofibroblasts in tubulointerstitial fibrosis 
(Iwano 2002). TGF-β treatment and contact injury to epithelial cells in vitro have 
shown that EMT is regulated by RhoA-mediated nuclear accumulation MRTF-A, 
which is crucial for inducing SMA expression (Fan 2007). 
The release and nuclear translocation of cytoplasmic MRTF on actin 
polymerization prompts SRF-directed target gene activation. SRF is a member of 
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the MADS (MCM1, Agamous, Deficiens, SRF)-box transcription factor family 
which mediates homodimerization, transcriptional cofactor recruitment and 
specificity (D.-Z. Wang2002). MRTF-A localizes in the nucleus in response to 
falling concentrations of cytoplasmic G-actin (Vartiainen 2007). Once in the 
nucleus, MRTF-A drives transcription of cytoskeleton genes, including α-SMA. 
Myocardin family members interact with SRF as homo- or heterodimers as a 
leucine-zipper and stimulate transcription via conserved CArG box DNA 
elements (Norman 1988). In Srf(-/-) embryonic stem cells, myocardin and MRTFs 
are unable to transactivate SRF-dependent promoters, confirming the obligate 
role of SRF as a facilitator of transcriptional activities of these factors (D.-Z. 
Wang2002). Interaction has been mapped to the basic residue-rich and 
glutamine-domain of MRTFs (Shore 1995). Whereas the MRTF N-terminal 
sequences act to inhibit MRTF-SRF complex formation, the C-terminus has a 
transcriptional activation domain (TAD) that is subjected to phosphorylation in 
response to serum stimulation in fibroblasts, and is key for transcription co-
activation and RNA polymerase interaction (Miralles 2003). 
In animal models, MTRF-A knockout mice are viable, however, 
homozygous knockout females are defective in lactation and mammary 
myoepithelial cell differentiation (Li 2003; Z. Wang 2003). These cells are 
necessary to supporting luminal epithelial cell growth and generation of 
contractility necessary for milk secretion. Collagen is a direct target of MRTF-A 
signaling through TGF-β and Rho activity. MRTF-A (-/-) mice are resistant to 
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cardiac fibrosis, as they are not prone to cardiac rupture nor increased lethality 
post-myocardial infarction (Small 2010). Cardiac fibrosis following ANG II 
treatment is reduced in MRTF-A deficient mice. Additionally, recent studies with 
ApoE(-/-) mice suggest a reciprocal change between myocardin and MRTF-A 
mRNA and protein expression mediated by miR-1. In injured arteries and aortic 
tissues containing atherosclerotic lesions, MRTF-A mRNA and protein 
expression is significantly increased, whereas myocardin expression is 
reciprocally decreased. Furthermore, loss or inhibition of MRTF-A reduced cell 
migration and proliferation in response to stimuli (Minami 2012). 
Collagen Gene Regulation 
Transcriptional Regulation of Collagen type I 
The collagens are the most ubiquitous and prevalent proteins in body, with 
at least 27 collagen types compose of approximately 42 distinct polypeptide 
chains (Myllyharju 2004). The fundamental structure of a  mature collagen type I 
protein consists of three polypeptides arranged in a triple helical rod formation of 
300 nm by 1.5 nm with an approximate molecular weight of 285 kDa (Hames 
2005). The triple helical type I collagen molecule, primarily present in skin, bone, 
and tendon, is the most abundant up-regulated protein in fibrosis. Collagen type I 
consists of two cha 
ins of α1(I) and one chain of α2(I), each containing a central triple helical 
domain of 338 repeats of a Gly-X-Y triplet (“Y” typically being hydroxyproline), 
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encoded by separate genes (COL1A1 and COL1A2). Human pro-COL1A1 and 
pro-COL1A2 genes are located at 17q21.31-22.05 and 7q21.3-22.1, respectively 
(Ghosh, 2002). Human COL1A1 is 18 kb in size consisting of 51 exons, whereas 
human COL1A2 is 38 kb in size consisting of 52 exons (Chu 1984; de Wet 1987). 
Factors involved in the regulation of the COL1A1 promoter with 
transcriptional regulation has been reviewed (Ghosh 2002). Upstream elements 
in COL1A1 promoter region (3.6 kb of the start site) are required to drive reporter 
expression uniformly in fibroblasts, osteoblasts, and vascular smooth muscle in 
transgenic animals (Bedalov 1994). Using the reporter green fluorescent protein 
(GFP), the 2.3-kb rat COL1A1 promoter fragment, (pOBCol2.3GFPemd) in mice is 
highly expressed in bone whereas the larger construct (pOBCol3.6GFPtpz) 
exhibits more uniform fluorescence, particularly in the skin (I. Kalajzic 2002). CBF 
(CCAAT binding factor) promotes human COL1A1 gene expression via 
interaction with a CCAAT box located at -100 to -96 bp, but not one at -125 to -
121 bp (Saitta 2000). Two upstream mouse COL1A1 control elements located at 
-190 to -170 bp and -160 to -130 bp repress collagen transcription upon binding 
inhibitor factor IF-1 (Karsenty 1990). Two GC-rich 12-bp repeat sequences 
between -133 and -71 bp interact with IF-2. Each repeat is preceded by a 
CCAAT motif which interacts with CBF with greater binding affinity than IF-2 and, 
thus, CBF binding inhibits the binding of IF-2 (Karsenty 1991). Through induction 
of LIP (p20 C/EBP-β) and C/EBP-δ, TNF-α inhibits mouse COL1A1 promoter 
activity in rat hepatic stellate cells, whereas overexpression of C/EBPβ stimulates 
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mouse COL1A1 promoter activity in HepG2 cells at the -365 to -335 bp region 
(Houglum 1994). The proteins Sp1 and Sp3 have been shown to interact 
between -129 to -107 in human skin and lung fibroblasts, where excess Sp3 can 
block Sp1-stimulated promoter activity. Sp1-binding activity at this region is 3- to 
4-fold stronger in SSc fibroblasts than normal fibroblasts (S. J. Chen 1998). Two 
additional inhibitory Sp1 tandem binding sites are located in a 274 bp intronic 
sequence (Liska 1992). Overlapping NF1 and Sp1 binding sites at the -138 to -77 
region act as a switch element. COL1A1 promoter activity is repressed though 
p65-dependent Sp1 binding sites near -220 bp (Nehls 1992). The G-rich A1 
region between -194 and -168 of mouse COL1A1 promoter is activated by c-Krox 
interaction. Interestingly, the analogous human COL1A1 promoter region 
between -195 and -168 bp fails to interact and possibly is not involved in 
transcriptional regulation (Peterkofsky 1999). 
The cis-acting elements involved in the transcriptional regulation of the 
COL1A2 promoter have also been reviewed (Ramirez 2006). The minimal 
promoter necessary to induce the COL1A2 human gene expression was 
determined to range between -380/+54 base pairs relative to the start site of 
transcription (Boast 1990). The proximal promoter is under control of trans-acting 
factors which bind four clusters of cis-acting elements in both a positive and 
negative manner. DNA elements at around −300 are bound by C/EBP, Ets, AP1, 
and Sp1 proteins. Activation of COL1A2 has been shown to require binding of 
the zinc-finger stimulatory protein 1 (SP1) to the GC-rich sequence near -300bp 
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(Inagaki 1994). Smad2 and Smad3 transactivation of the α2(I) collagen gene by 
TGFβ signaling necessitates binding to the conserved Smad Binding Element 
(SBE) sequence, CAGAC, located downstream of the Sp1 sites (Nehls 1993). 
Two Ets1 sites flank this site just downstream. Collagen transcription has been 
shown to be activated by binding of Ets1, yet inhibited through binding of Fli1 to 
the same box region (Czuwara-Ladykowska 2002; Oikawa 2003). A repressive 
C/EBP site also exists which has been shown to bind C/EBPβ upon TNFα and 
IFNγ stimulation (Ghosh 2006; Greenwel 2000). However, C/EBPβ 
overexpression induces human COL1A2 promoter activity in primary culture of 
foreskin fibroblasts (Ghosh 2006). Two TCC- enriched regions located between 
−160 and −125 interacting with Sp1, Sp3 and c-Krox both activate and repress 
COL1A2 expression depending on the cell type (Ihn 1996). A recognized 
COL1A2 activating CCAAT motif near -80 is identified by the CBF/p300/NF-Y 
trimer (Iraburu 2000). Finally, a methylation-responsive CpG site at +7 is bound 
by RFX/CIITA proteins which repress collagen transcription when the site is 
methylated or during IFNγ treatment (Emery 1996). CIITA activity is regulated by 
posttranslational modifications such as ubiquination, acetylation and 
phosphorylation (Wu, X. 2009) 
Post-transcriptional Regulation 
The structure of collagen mRNA contains regulatory elements for protein 
interaction in the 5’ and 3’ untranslated regions (UTRs). The interaction of 
heterogenous nuclear RNA binding proteins (hnRNPs) and complex formation on 
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collagen 3’UTRs of the COL1A1 gene may increase or hamper mRNA 
association with the ribosome (Chu 1985; B. Stefanovic 1997). Additionally, 
response of pro-αI(I) collagen gene mRNA is specifically destabilized in 
suspended cells when compared to adherent cells. Changes in pro-αl(1) collagen 
mRNA half-life were found to correlate well with the changes in the cellular 
adhesive state (Holcik 1997). Often located within the UTRs of mRNA transcripts 
are target sequences that bind inhibitory or degradatory micro-RNAs (miRNAs). 
Down regulation of miRNAs levels, such as mir-29, have been shown via 
phosphor-SMAD3 binding in TGF-β signaling (Qin 2011). Translation initiation 
factor (eIFs) recruitment and mRNA circularization are required events for mRNA 
translation involving the cytoplasmic poly(A)-element binding protein (CPEB) and 
poly(A)-binding protein (Gallie 1998; Wakiyama 2000). Dimerization of the 
collagen mRNAs at the 5’UTR stem-loop structures are thought to be important 
for peptide translation and triple helix formation in the endoplasmic reticulum 
(ER) (Rossi 1987; Branko 2003). 
The two chains of collagen are translocated to the lumen of the rough ER 
during translation. In the ER, proline and lysines are hydroxylated by specific 
hydroxylases allowing formation and stabilization of the triple helix (Bansal 1988; 
Yamauchi 2012). Hydroxylation of proline stabilizes the triple helix and allows for 
secretion of collagen. Ascorbate stimulates the post-translational hydroxylation of 
prolyl- and lysyl-residues in the lumen of the ER (Peterkofsky 1991). 
Consequently, ascorbate stabilizes the triple helical structure and stimulates 
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procollagen secretion (Rosenblat 1998). After exocytosis via vesicular transport 
into the ECM, procollagen is further modified by procollagen peptidases, which 
cleave the N- and C-termini, yielding tropocollagen which align with non-
symmetrical ¼ stagger with 40 nm gaps between tropocollagens (D. J. S. 
Hulmes 2002; D. J. Hulmes 1992). Adjacent rows are displaced by approximately 
67 nm, and the structure repeats every five rows, providing a characteristic 
striated pattern (Orgel 2006). The enzyme lysyl oxidase stabilizes covalent cross-
linking of collagen molecules, greatly increasing tensile strength. Formation of a 
hydroxypyridinium ring between one lysyl and two hydroxylysyl residues is 
another form of cross-linkage, which is unique to collagen (Eyre 1980). As stated 
previously, MMPs play a role in ECM turnover. These enzymes cleave the triple 
helix of collagen approximately three quarters from the N-terminus, destabilizing 
the protein. Non-specific proteases then degrade the collagen α-chains (Nagase 
1999). 
Previous Work in Laboratory 
Previous work in the Smith lab demonstrated an important role for MRTF-
A in myofibroblast collagen gene regulation in connection with the known role for 
MRTF-A in SMA gene expression (Luchsinger 2011). CArG-dependent and 
CArG-independent mechanisms of collagen gene expression were identified in 
lung fibroblasts. Our working model is that MRTF-A activates collagen 
transcription through Sp1 family and SRF through noncanonical CArG sites 
within the COL1A2 proximal promoter. This mechanism appears to differ relative 
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to other SRF-dependent genes such as SMA, which are dependent on MRTF-
SRF complex formation to achieve efficient activation. 
First, in both the collagen and SMA promoter in lung fibroblasts, MRTF-A 
associates with SRF in the region of the CArG box-like elements. Collagen and 
SMA protein levels were stimulated in IMR90 human lung fibroblasts with 
overexpression of MRTF-A, whereas overexpression of a dominant negative 
MRTF-A reduced collagen protein levels. Protein synthesis and hnRNA levels of 
collagen were reduced with a knockdown of MRTF-A. Additionally, MRTF-A 
activation of the collagen promoter was reduced with the loss of known Sp1 sites 
in lung fibroblasts. However, this was not observed with deletion or mutation of 
the SMAD-binding site. 
Second, a novel mechanism of MRTF-A transactivation of the collagen 
promoter via Sp1 interaction was described, where disruption of Sp1 family 
binding to DNA with mithramycin A inhibits collagen expression but not SMA 
expression. This indicates MRTF-A activation of collagen has a mechanistic 
difference in comparison to SMA expression. It was demonstrated that MRTF-A 
relies on Sp1 in a synergistic manner to stimulate collagen expression. Reporter 
gene assays were performed in Drosophila melanogaster cells (D-Mel.2). Co-
transfection of MRTF-A and SRF lead to an approximate 4-fold increase in 
reporter activity, whereas MRTF-A and Sp1 co-expression displayed a greater 
than 10-fold increase of collagen type I promoters. 
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Finally, mutation of the transcriptional activation domain within SRF is 
deleterious for transcriptional activation of SMA, although no effect was observed 
on collagen promoter activity. Loss of MRTF-A in knockdown and murine knock-
out models shows an inhibition of collagen and SMA expression, suggesting a 
disruption of myofibroblast function. The incorporation of collagen promoter GFP 
constructs into the transgenic mice provides a quantitative measure of 
transcription activity by a collagen promoter. MRTF-A KO mice were crossed with 
pOB3.6COLGFPtpz transgenic mice by the Smith lab in order to observe the 
function of MRTF-A on collagen transcription regulation in vivo. Isolation of cells 
containing an integrated construct from KO and WT transgenic mice allowed for 
the measurement of transcription activity of collagen expressing cells with and 
without functional MRTF-A. The presence of the pOB3.6COLGFPtpz transgenic 
reporter was confirmed by PCR of genomic DNA. Cells isolated from lungs of 
transgenic mice have been visualized by fluorescent and confocal imaging, 
revealing substantial attenuation of COL-GFP reporter fluorescence in KO cells 
(Luchsinger 2011).  
Recent work in our lab has focused on the nuclear translocalization of 
MRTF-A upon TGF-β activation. MRTF-A bound to the polypeptide protein tag 
FLAG has shown MRTF-A is strongly localized in the nucleus upon 150pM TGF-
β stimulation. This was not seen with the introduction of 1.0 μM of the TβR-1 
inhibitor SB431542 (data not shown), which blocks the kinase activity of TβR-1, 
arresting the transmission of TGF-β signal. MRTF-A activation in the nucleus is 
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important for myofibroblast differentiation, as previous work in our lab has shown 
collagen and SMA protein levels in MRTF-A KO lung cells are blunted compared 
translocates to  the nucleus in fibrosis and SSc through TGF-β signaling. 
Specific Aims 
The purpose of this study is to explore the relationships between MRTF-A 
and collagen synthesis in fibrotic disease, particularly SSc. The following are 
hypothesized: 1) MRTF-A is dysregulated and/or activated by translocation into 
nucleus in skin cells of SSc patients, 2) HDFs can be used as a model system to 
examine the role of MRTF-A in regulating collagen synthesis, 3) TGF-β 
stimulates nuclear localization of MRTF-A and 4) A loss-of-function mutation of 
the MRTF-A gene lowers collagen transcription and secretion as well as TGF-β 
signaling. 
Question 1: Is MRTF-A activated by translocation into nuclei in the skin of 
SSc patients when compared to normal skin? 
Question 2: Do human dermal fibroblasts (HDF) synthesize collagen 
similar or differently to fetal lung fibroblasts (IMR90) in the presence or absence 
of TGFβ? 
Question 3: Does TGF-β influence MRTF-A up-regulation, nuclear 
translocation and collagen secretion in HDFs? 
Question 4: Is collagen transcription and secretion in response to TGF-β 
or angiotensin (ANG II) disrupted by a loss of function mutation of the MRTF-A 
gene in murine lung fibroblasts? 
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II. Methods 
Knockout Mouse Lines 
MRTF-A KO mice were previously crossed two generations with COL-
GFP transgenic mice to generate MRTF-A/GFP mice by the Smith lab. MRTF-A 
KO mice were provided by Dr. Eric Olson (U.T. Southwestern) (Li 2006). 
Transgenic mice carrying the 3.6kb proximal promoter of the rat COL1A1 gene 
driving topaz GFP (pOB3.6COLGFPtpz) were provided by Dr. David Rowe (U. 
Conn. Medical Center) (I. Kalajzic 2002; Z. Kalajzic 2008). 
Genotyping 
Genotyping of the MRTF-A KO allele and genomic incorporation of the 
COL-GFP transgene was analyzed by PCR analysis. Genomic DNA was 
extracted from tail biopsies in 250 μL Direct PCR Lysis Reagent-Tail (Viagen 
Biotech) and 6 μL Preoteinase K solution (Fisher) in 1.5mL microcentrifuge 
tubes. The solution was rotated in a hybridization oven overnight at 55°C and 
then at 85°C for 40 minutes. The solution was centrifuged at 12,000 xg for 2 
minutes to pellet hair. The supernatant was transferred to a new microcentrifuge 
tube (MCT)and samples were stored at -20°C until used. 1 μL of lysate was used 
per PCR reaction. The lysate sample was mixed with 17.375 μL water, 5 μL 5x 
Crimson Taq Reaction Buffer (New England BioLabs), 1 μL primer set 
(Integrated DNA Technologies) (Table 1), 0.5 μL 10 mM dNTP mix (Invitrogen) 
and 0.125 μL Crimson Taq DNA Polymerase (New England BioLabs). Cycling  
26 
 
Table 1: Mouse PCR Primer Sequences 
Primer Sequence 
GFP Topaz Allele 
Forward primer: 
Reverse primer: 
 
5’-TCATCTGCACCACCGGCAAGC-3’ 
5’-AGCAGGACCATGTGATCGCGC-3’ 
MRTF-A KO Allele 
GT5: 
GT6: 
LacZ3-QB: 
 
5’-GTTGCTCAGTCATGTGACACCTGTACAG-3’ 
5’-GCCTTCAGTACCTTCCTAAGCTCTGCAG-3’ 
5’-CATGGTGGATCCTGAGACTGGCGAATT-3’ 
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conditions were run using PTC-200 (Table 2). Samples were run on a 1.5% 
agarose gel at 110 V for 20 min in 1X TAE and visualized using a Kodak Image 
Station 440CF. 
Isolation of Primary Murine Lung Fibroblasts 
Mice 3-6 weeks old were euthanized via CO2 asphyxiation. Lungs were 
perfused with 10 mL ice cold 1x DPBS + Ca2+, Mg+ by penetration of the right 
ventricle. Lungs were trimmed of connective tissue and rinsed three times in ice 
cold 1x DPBS and minced into <1 mm pieces and rotated in 3mL/mouse of 
digestion buffer; (1x DPBS +Ca2+/Mg+, 500 U/mL dispase (BD Bioscence), 1 
mg/mL Collagenase Type 1-Filtered (Worthington) and 9 kunitz DNase 
(Worthington) at 37°C for 40 minutes using a hybridization oven. The digestion 
mixture was filtered through a 100 μm nylon cell strainer (BD Falcon) and 
neutralized with >30 mL warm 10% FBS-DMEM. Cells were centrifuged at 200 
xg for 5 minutes at room temperature, cells were resuspended in 6 mL/mouse 
10%-FBS DMEM and plated on 100 mm plastic tissue culture dishes (BD Falcon) 
for 24 hours in 5% CO2 at 37°C. Cells were washed with warm 1X PBS and re-
fed with 10% FBS-DMEM. Established cell cultures were allowed to reach 
confluence and were split at a ratio of 1:2 or 1:3. Cultures between passages 1 
and 3 were used for all experiments. 
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 Table 2: Genotyping cycling conditions. 
MRTF-A GFP Topaz 
 
Stage 1 
  94°C                                        2 min 
1 cycle 
 
Stage 2 
  94°C                                      20 sec 
  57°C                                      30 sec 
  72°C                                      45 sec 
30 cycles 
 
Stage 3 
  72°C                                        1 min 
  4°C                                           Hold 
1 cycle 
 
Stage 1 
  94°C                                         2 min 
1 cycle 
 
Stage 2 
  94°C                                       30 sec 
  65°C                                       30 sec 
  72°C                                       40 sec 
3 cycles 
Stage 3 
  94°C                                       30 sec 
  62°C                                       30 sec 
  72°C                                       40 sec 
30 cycles 
 
Stage 4 
  72°C                                         5 min 
  4°C                                            Hold 
1 cycle 
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  Tissue Culture Cell Lines, Maintenance and Treatment 
Human Dermal Fibroblasts (HDF) with population doubling (PDL) values 
between 7 and 20, IMR90 fetal lung fibroblasts with PDL values between 28 and 
39 and primary murine lung fibroblasts were grown in Dulbecco’s Minimal 
Essential Media (DMEM) with 4.5g/L glucose and sodium pyruvate (Corning) 
supplemented with 10% fetal bovine serum (FBS) (Atlanta Biological), 1% 
penicillin/streptomycin (Corning) and 1% L-Glutamine (Corning) vacuumed 
filtered through a 0.22 μm polyethersulfone membrane (Corning). Cells were 
grown in 5% CO2 at 37°C. Cells were passaged after washing with 1x PBS using 
0.25% Trypsin/EDTA which was neutralized at a 1:2 ratio with 10% FBS-DMEM. 
Cells were counted using a hemocytometer. Cells were routinely plated in 10 mL 
10% FBS-DMEM at 1x105 to 1x106 cells per 100mm plastic tissue culture dish. 
Media was changed every two to three days.  
For treatment, cells were allowed to adhere for 24 hours at the indicated 
density in 10% FBS-DMEM and then washed twice with 1x PBS. Cells treated 
with TGFβ were starved for 24 hours with 0.4% FBS-DMEM followed by 
incubation with or without 4 ng/mL hrTGFβ-1 (R&D Systems) for 4 to 48 hours. 
Cells treated with ANG II were starved for 24 hours with 0.4% FBS-DMEM 
followed by incubation with or without 100 nM ANG II for 24 to 48 hours. Cells 
treated with SB431542 were starved for 24 hours with 0.4% FBS-DMEM followed 
by incubation with or without 5μM SB431542 (Sigma) for the indicated time. 
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Whole Cell Protein Extraction 
Cell cultures were washed twice with ice-cold 1x PBS. RIPA extraction 
buffer (25mM Tris pH 7.4, 50nM NaCl, 0.5% sodium deoxycholate, 2% NP-40, 
0.2% SDS, 10μL/mL 1x Protease Inhibitor Cocktail [Activ Motif]) was then added 
to the cell monolayer and cells were scraped using a pre-chilled cell scraper and 
transferred to a pre-chilled 1.5 mL MCT. Lysates were chilled at 4°C with 
constant agitation on an orbital shaker for 15 minutes and centrifuged at 15,000 
xg for 15 minutes at 4°C. The supernatant was transferred to a pre-chilled MCT 
and stored at -80°C until used.  
Separation of Nucleus and Cytoplasm Extracts 
Nuclear and cytoplasmic extracts were isolated using the Thermo 
Scientific NE-PER Nuclear and Cytoplasmic Extraction Kit. In order to extract 
nuclear and cytoplasmic components, at least 1x106 cells were plated and 
treated as previously described. Cells were washed with 1x PBS and harvested 
using 2.5 mL 0.25% Trypsin/EDTA. Cells were centrifuged at 500 xg for 5 
minutes at room temperature and resuspended in 1mL 1x PBS. Cells were 
transferred to a 1.5 mL MCT and centrifuged at 500 xg for 5 minutes. The 
supernatant was discarded, leaving the cells as dry as possible and 100 μL ice-
cold of Cytoplasmic Extraction Reagent I (CERI) was added with 1 μL Protease 
Inhibitor Cocktail. The pellet was mixed using a vortex mixer for 15 seconds, 
incubated on ice for 10 minutes and 7 μL CERII was added. The suspension was 
mixed for 5 seconds and incubated on ice for 1 minute. The suspension was 
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mixed again for 5 seconds and centrifuged at 14,000 RPM for 10 minutes. The 
supernatant (cytoplasmic extract) was immediately transferred to a pre-chilled 
MCT and stored at -80°C until used. The remaining pellet was suspended in 50 
μL Nuclear Extraction Reagent (NER) with 0.5 μL Protease Inhibitor Cocktail and 
mixed for 15 seconds. The suspension was chilled on ice and mixed for 15 
seconds every 10 minutes for a total of 40 minutes. The suspension was 
centrifuged at 14,000 RPM for 10 minutes. The supernatant (nuclear extract) was 
transferred to a pre-chilled MCT and stored at -80°C until used. 
Bicinchoninic Acid (BCA) Microplate Protein Assay 
Extracts were quantified in triplicate for protein quantification by BCA 
method (Pierce) in a clear 96-well plate. In each well, 5 μL of vortexed sample 
was diluted in 20 μL water and 200 μL working reaction reagent (50:1 ratio of 
Reagent A:Reagent B). The plate was covered and mixed on an orbital shaker at 
low setting for 1 minute and incubated at 37°C for 30 minutes. Samples were 
measured at A562 and quantified using the linear regression from a serially diluted 
Bovine Serum Albumin (BSA) curve. 
Western Blot Analysis 
Equivalent amounts of sample ranging from 5 to 20 μg protein were 
separated via SDS-Page analysis on either a Novex 4-12% (Invitrogen) or a 4-
20% Mini-PROTEAN TGX (BioRad) gradient gel. Samples were denatured in 4x 
or 6x sample buffer (250 mM Tris, 10% SDS, 30% glycerol, 5% β-
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mercaptoethanol, 0.02% bromophenol blue, pH 6.8) at 90-100°C for 5 minutes 
and cooled to room temperature. Samples were electrophoretically separated 
using 4°C 1x running buffer (25 mM Tris, 192 mM glycine, 0.1% SDS) at a 
constant voltage potential of either 120V for Invitrogen gels or 200V for BioRad 
gels until the bromophenol blue was at the bottom of the gel. Samples were 
transferred onto a 0.45 μm nitrocellulose membrane using a constant 22V at 4°C 
overnight using 1x transfer buffer (48mM Tris, 39 mM glycine, 20% methanol, 
0.037% SDS,). Membranes were soaked in 10 mL Ponceau S solution (Sigma) 
to verify protein transfer and washed three times with 10 mL distilled water for 5 
minutes. Membranes were blocked in 10 mL 4% milk in TBST (25mM Tris pH8.0, 
125mM NaCl, 0.1% Tween) for 40 minutes and incubated with primary antibody 
in 10 mL 4% milk/TBST for 3 to 24 hours (Table 3). Membranes were washed 
briefly with distilled water and incubated three times with 10 mL 4% milk/TBST 
for 15 minutes. Membranes were incubated with horseradish peroxidase-
conjugated secondary antibody in 10 mL 4% milk/TBST for 2 to 24 hours. 
Membranes were again washed briefly with distilled water and incubated two 
times with 10 mL 4% milk/TBST for 15 minutes followed by two washes with 10 
mL TBST for 10 minutes. Membranes were briefly blotted on Whatmann paper 
and were visualized using ECL and Femto detection with a Kodak Image Station 
440CF. Recycled membranes were washed four times in 10 mL TBST for 5 
minutes and then incubated for 15 minutes in 15 mL Pierce Stripping Solution at  
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Table 3: Western Blotting Antibody Dilutions 
 
Antibody Primary 
Dilution 
Primary 
Time 
Secondary 
Dilution 
Secondary 
Time 
Gtα MRTFA 
C-19 
(Santa Cruz) 
 
1:200 Overnight 1:5000 Overnight 
Msα GAPDH 
(Santa Cruz) 
 
1:400 3-4 hours 1:700 1-2 hours 
Gtα Collagen I 
(Southern Bio) 
 
1:200 3-4 hours 1:2000 1-2 hours 
Msα GAPDH 
(6C5) (Santa 
Cruz) 
1:200 3-4 hours 1:2000  1 hour 
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room temperature. The membranes were washed three times in 10 mL TBST for 
10 minutes. The Western procedure was then repeated, starting with blocking. 
Western Blot Analysis of Collagen Secretion 
Cells were allowed to adhere for 24 hours in 10% FBS-DMEM. Cells were 
washed two times with 1x PBS and starved and treated as previously described 
with 0.4% DMEM supplemented with 250 μM ascorbate. Media was collected 
and treated with 10μL/mL Protease Inhibitor Cocktail (Activ Motif) and stored at -
80°C until used. Media samples were precipitated proportional to whole cell 
lysate concentration using a 1:3 ratio of 100% ethanol overnight at -80°C in a 15 
mL conical tube. Precipitates were centrifuged at 3400 RPM for 10 minutes at 
4°C using an IEC Centra Cl2 centrifuge and the supernatant was discarded. The 
pellets were resuspended in 40 μL PBS and 15 μL 4x sample buffer and loaded 
onto 4-20% SDS-Page gels. 
Sircol Assay for Total Collagen 
The Sircol assay was performed essentially as described (Marotta & 
Martino, 1985). Secretion of collagen in media was assayed using either volume 
normalized to protein concentration of whole cell lysates or equivalent volumes. 
At the time of collection, media was precipitated as described above.  The pellet 
was resuspended in 1.1 mL Sircol Dye Reagent (BioColor, U.K.) and transferred 
to a 2 mL LoBind Eppendorf MCT (Sigma) and agitated on an orbital shaker at 
240 RPM for 30 minutes at room temperature. Precipitated collagens were 
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pelleted at approximately 14,300 Xg for 10 minutes. The supernatant was 
carefully discarded using 1000 μL flat-tip and 200 μL long-tip pipette tips so as 
not to disturb the pellets. Residual dye was discarded and the MCTs were dried 
using two sterile cotton swabs. Pellets were resolubilized in 0.5M NaOH, 
vortexed for 5 seconds and agitated using an orbital shaker at 240 RPM for 10 
minutes. In triplicate, 200 μL of each sample were transferred to a clear 96-well 
plate and measured at A555. Samples were quantified using linear regression 
from a serially diluted collagen standard curve.  
Histological Preparation of SSc and normal skin 
A total of 5 healthy control and 9 scleroderma skin samples.were provided 
by Dr. Robert Lafyatis at Boston University School of Medicine Scleroderma 
Center of Research Translation. Staining was provided by the 
Dermatopathology Core/Skin Pathology Laboratory at Boston University School 
of Medicine. Slides were stained with 1:2000 MRTF-A (C19, Santa 
Cruz)Development was then done with DAB and counterstained with 
hematoxylin. A blocking peptide antigen was used to determine specificity.  
Image Quantification 
 Images were captured on an Olympus IX-70 inverted microscope 
equipped with a mercury arc source lamp.  for fluorescent (nonstandard settings 
used for images shown: exposure, 22.97 sec; target, 71%; phase, 2; gain, 1) and 
nonflourescent (exposure, 578.07 msec; target, 71%; gain, 1) images. 
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Fluorescent samples were excited using the 488 excitation line and emission was 
filtered using a 520 ± 20 nm bandpass filter. Quantification of fluorescent signal 
was achieved using ImageJ (NIH) analysis software. Images were converted to 
8-bit images and signal above set threshold was considered positive signal. 
Ordinal scale quantification of the fluorescence signal was determined by 
drawing an outline around the border of the cell (edges included) with positive 
signal and determining the integrated density within this region. 
Statistical Analysis 
 Statistical analyses were computed using IBM SPSS Statistics 20 
software suite. Experimental values were analyzed using one-way ANOVA. 
Statistical differences between groups were identified using Sheffe’s post-hoc 
analysis. Analysis of histological samples was scored and analyzed using 
nonparametric Mann-Whitney U. A two-tailed p-value less than 0.05 were 
considered statistically significant. 
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III. Results 
 
Epidermal MRTF-A nuclear localization is prominent in SSc 
patients 
In order to test the hypothesis that MRTF-A activation by translocation into 
nuclei is enhanced in SSc patients, histological slides of normal and SSc 
patients, provided by Dr. Robert Lafyatis at Boston University School of 
Medicine, were stained with MRTF-A (C19) antibody and counterstained with 
hematoxylin by the Dermatopathology Core/Skin Pathology Laboratory at Boston 
University School of Medicine. Interpretation of the staining was aided by Dr. 
Lafyatis. A total of 5 control, normal skin samples and 9 scleroderma samples 
were examined. Staining was strongest in epithelial structures (Figure 1, A & B). 
Samples from one scleroderma patient stained with IgG control and an MRTF-A 
blocking peptide contained little background staining indicating that MRTF-A 
staining was specific (Figure 1, C&D). Nuclear MRTF-A localization of the 
epidermal layer was scored by counting the brown and blue nuclei within the 
epidermis to assess the nuclear location of MRTF-A. Cytoplasmic localization of 
MRTF-A was ignored due to increased melanin production in the epidermal layer. 
SSc samples had significantly more MRTF-A nuclear localization in the 
epidermal layer of the skin in comparison to normal samples (Figure 2). 
Interestingly, there was no prominent staining in areas typical of myofibroblasts 
within the deep dermis of the scleroderma skin. Most striking, nuclear MRTF-A  
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Figure 1. Scleroderma (SSc) nuclei in keratinocytes contain more MRTF-A 
staining than normal nuclei. Histological samples of A) healthy control (n=5) 
and B) scleroderma (n=9) human skin were stained with 1:2000 MRTF-A 
antibody (Santa Cruz C-19) and counter stained with hematoxylin. C) Nonspecific 
IgG staining scleroderma sample. D) MRTF-A blocking peptide staining of 
scleroderma sample. Green arrows points to MRTF-A localized in nuclei. Blue 
arrows point to nuclei without MRTF-A.  SSc samples in figure are from the same 
patient. Images were taken at 10X. 
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Figure 2. Epidermal scleroderma (SSc) nuclei contain more MRTF-A 
staining than control. Histological samples of healthy control (n=5) and 
scleroderma (n=9) human skin were stained with 1:2000 MRTF-A antibody 
(Santa Cruz C-19) and counter stained with hematoxylin. Total cells with MRTF-
A nuclear localization in the epidermal layer were counted and compared with the 
total amount of cells in the epidermal layer. Data were analyzed using 
nonparametric Mann-Whitney-U (p<0.01). 
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staining was more prominent in the microvasculature in scleroderma samples in 
endothelial and perivascular cells which could be either pericytes or inflammatory 
cells. MRTF-A expression in the nuclei of perivascular cells are not seen in 
normal skin (Figure 3). MRTF-A was not overly expressed in SSc myofibroblasts, 
but is abnormal in perivascular region. 
Comparison of IMR90 and HDF collagen up-regulation and 
secretion. 
Previous work in the laboratory focused on MRTF-A in lung IMR90 cells. 
For over three decades, IMR90 cells, derived from human female fetal lung, have 
served as a model of fibroblasts in a wide variety of studies (Ehler, Babiychuk, & 
Draeger, 1996; Nichols et al., 1977). Since scleroderma begins with skin lesions 
and is at risk of progressing to visceral organs such as the lungs, human dermal 
cells were compared to human lung cells. To determine whether baseline 
synthesis is greater in HDFs, procollagen synthesis by IMR90 and HDF lysates 
supplemented with 250 μM ascorbate were compared. Procollagen synthesis by 
Western analysis in triplicate IMR90 lysates supplemented with ascorbate is 
shown in Figure 4. Westerns were run with three concentrations of rat tendon 
collagen standards and used as a standard curve. Densitometry of western blots 
of both cell types indicated that there was significantly more procollagen in HDF 
cell lysates in comparison to IMR90s relative to collagen standards (Figure 5, 
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p<0.05). Analysis of total collagen secretion in the presence of ascorbate with 
and without TGF-β was determined by the Sircol method as  
 
Figure 3. MRTF-A perivascular and endothelial nuclear staining is 
prominent in SSc. Histological samples of A) healthy control (n=5) and B) 
scleroderma (n=9) human skin were stained with 1:2000 MRTF-A antibody 
(Santa Cruz C-19) and counter stained with hematoxylin. Brown arrow indicates 
perivascular staining. Green arrows points to endothelial staining. Images were 
taken at 10X.
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Figure 4. Procollagen expression is observed in IMR90 lysates. IMR90 (PDL 
30) cultures were plated in 10%-FBS-DMEM and grown to >90% confluence. 
Cells were then treated for 48 hours in 0.4%-FBS-DMEM supplemented with 250 
μM ascorbate. Media was changed after 24 hours. Protein levels were 
normalized to 15μg total protein levels in the whole cell lysates, separated on a 
4-12% Invitrogen gel. After transfer to nitrocellulose, proteins were visualized by 
Western blot using antibodies for collagen I and GAPDH.
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Figure 5. Untreated human dermal fibroblasts synthesize more collagen 
than IMR90 fibroblasts. IMR90 (PDL30) and HDF (PDL9) cultures (n=3) were 
plated in 10%-FBS-DMEM and grown to >90% confluence. Cells were then 
starved for 24 hours in 0.4%-FBS-DMEM supplemented with 250 μM ascorbate 
for 48 hours. Media was changed at 24 hours. Protein levels were normalized to 
15μg total protein levels in the whole cell lysates, separated on a 4-12% 
Invitrogen gel. After transfer to nitrocellulose, proteins were visualized and 
analyzed by Western blot for collagen I levels relative to collagen standards. 
(p<0.05). 
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previously described (Marotta 1985). HDFs without TGF-β secreted 48.8% more 
collagen in comparison to IMR90 fibroblasts (Figure 6). Collagen secretion 
trended up in both cell lines upon treatment with TGF-β but did not reach 
significance (Figure 6).  
TGF-β stimulates cytoplasmic and nuclear MRTF-A in human 
dermal fibroblasts. 
TGF-β stimulates translocation of MRTF-A to the nucleus in a cell specific 
manner (Hinson 2007). In order to determine the influence of TGF-β on this 
response in HDFs, nuclear and cytoplasmic extracts of HDF samples were 
obtained according to manufactuer’s instructions (Pierce). Samples were treated 
for 0, 4, 8 or 24 hours as described in methods in the presence or absence of 
TGF-β. At 4 hours there was an increase in cytoplasmic MRTF-A. At 8 hours with 
TGF-β the MRTF-A increases further whereas without TGF-β the MRTF-A 
decreases to base line (Figure 7). Nuclear localization of MRTF-A is seen in 
approximately equal amounts at 0, 4, and 8 hours. At 24 hours a greater amount 
of nuclear MRTF-A in cells stimulated with TGF-β.  
Knock Out of MRTF-A in Murine Lung Fibroblasts Disrupts 
TGF-β and ANG II Response In Vitro. 
The genetic disruption of MRTF-A causing a loss of function mutation has 
been achieved in mice (Li 2006). An advantage of using knockout mice is that the  
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Figure 6. Human Dermal Fibroblasts secrete more collagen than IMR90 
cells. Cultures were grown in 10%-FBS-DMEM for 24 hours to >90% confluence. 
Cells were then starved for 24 hours in 0.4%-FBS-DMEM supplemented with 250 
μM ascorbate for 24 hours and treated for another 24 hours with (black) or 
without (white) 4ng/mL TGFβ. Secreted collagen levels were measured in 
triplicate by the Sircol method normalized to total protein levels in the whole cell 
lysates. Figure is representative of two experiments. 
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Figure 7. Human Dermal Fibroblast MRTF-A responds to changing media 
and TGF-β. HDF cells (PDL 18) were plated for 24 hours in 10%-FBS-DMEM 
and starved overnight in 0.4%-FBS-DMEM. Cells were treated with or without 
4ng/mL TGFβ for the indicated amounts of time. Cytoplasmic and nuclear 
extracts were taken via NE-PER. Cell extracts were analyzed by Western Blot for 
MRTF-A (C19) and GAPDH. Top) Western Blot analysis of cytoplasmic MRTF-A. 
Bottom) Nuclear MRTF-A extracts from the same samples. Data is from one 
experiment. 
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homozygous deletion of the gene ensures all MRTF-A transcripts are  
nonexistent or nonfunctional within the cell. To analyze and help define the role 
of MRTF-A in the regulation of collagen transcription in vivo, MRTFA-KO mice 
were previously crossed with COL-GFP transgenic mice containing 
pOB3.6COLGFPtpz. To determine the importance MRTF-A on collagen 
synthesis and secretion, lung fibroblasts isolated from 3-6 week old MRTF-A WT 
and KO littermates were established in culture and monitored for the expression 
of collagen. PCR amplification of genomic DNA isolated from tail samples was 
performed to confirm homozygosity of the MRTF-A and COL-GFP alleles. 
Generation of these COL-GFP/MRTF-A KO mice allowed for measurement of 
collagen transcriptional activity in the presence or absence of MRTF-A. The 
expression of COL-GFP in the presence or absence of SB431542 with or without 
TGF-β or ANG II was visualized using an Olympus IX-70 inverted fluorescent 
microscope. Fluorescent images indicate a substantial decrease in COL-GFP 
reporter fluorescence in KO cells compared to (Figure 8). Both ANG II and TGF-β 
increased collagen transcription in WT but not KO fibroblasts (Figure 8). The 
intensity of fluorescence (Figure 9A) and the number of fluorescent cells (Figure 
9B) were measured in five fields on triplicate wells using ImageJ. TGF-β 
increased overall fluorescent intensity with a large variation between fields with 
little change in the numbers of fluorescent cells. ANG II showed a morphological 
increase in cell size with more concentrated labeling, but did not show a  
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Figure 8. Angiotensin and TGF-β up-regulate collagen transcription in 
MRTF-A WT but not in KO fibroblasts. MRTF-A WT and KO COL-GFP 
transgenic mouse primary lung fibroblasts were plated at same densities and 
grown to >90% confluence in 10%-FBS-DMEM. Cells were starved for 24 hours 
in 0.4%--FBS-DMEM + 250μM ascorbate and treated for an additional 48 hours 
in 0.4%-FBS-DMEM + 250uM ascorbate in the presence or absence of TGFβ 
(4ng/mL), 100nM AII and 5μM SB431542. Reporter fluorescence was acquired 
under an Olympus IX-70 inverted fluorescent microscope. Data are 
representative of two experiments. 
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Figure 9. Collagen transcription is down-regulated in MRTF-A KO lung 
fibroblasts. MRTF-A WT and KO COL-GFP transgenic mouse primary lung 
fibroblasts grown to >90% confluence in 10%- FBS-DMEM. Cells were starved  
for 24 hours in 0.4%-FBS-DMEM + 250μM ascorbate and treated for an 
additional 48 hours in 0.4% FBS-DMEM + 250μM ascorbate in the presence or 
absence of TGFβ (4ng/mL), 100nM AII and 5μM SB431542. Reporter 
fluorescence was acquired under an Olympus IX-70 inverted fluorescent 
microscope and analyzed using ImageJ. A) Total intensity measured per total 
number of fluorescent cells. B) Percentage of total cells exhibiting fluorescence. 
Data are representative of two experiments. 
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significant increase in fluorescent intensity when total fluorescence was analyzed 
per total number cells. Collagen transcription was inhibited in both WT and KO in 
the presence of SB431542 with and without TGF-β or ANG II (Figure 9A). Total 
average percentage of fluorescent KO cells (range 8.42-16.13% depending on 
treatment) were consistently lower in comparison to WT cells (range 20.80-
27.05%), but percentages remained relatively the same regardless of inhibitor 
treatment (Figure 9B). Collagen secretion was analyzed by the Sircol Method, 
which indicated no significant changes (data not shown).  
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 IV. Discussion 
While the pathogenesis of SSc remains unknown, the hallmark of both 
localized and diffuse SSc in the skin is the replacement of normal dermal 
architecture with excessive deposition of collagen and other connective tissue 
macromolecules. A study has shown that there is a sustained activation of genes 
encoding ECM proteins in cultured fibroblasts of SSc patients (Whitfield et al., 
2003). MRTF-A is a ubiquitously expressed protein linking actin dynamics and 
gene transcription (Olson 2010). Previous studies in our lab determined that 
MRTF-A regulates collagen promoter activity and production through both SRF 
and Sp1 complexes (Luchsinger 2011). Binding of G-actin to the RPEL domain 
sequesters MRTF-A in the cytoplasm, preventing its translocation into the 
nucleus (Hinson, Medlin, Lockman, Taylor, & Mack, 2007). Activation and 
translocation into the nucleus is promoted by actin polymerization and 
subsequent depletion of available G-actin. In our study, tissue and cellular 
localization of MRTF-A staining in SSc skin lesions (n=9) and normal healthy 
controls (n=5) was studied. Percentage of cells positive for nuclear MRTF-A was 
significantly higher in the epithelial layer of SSc patients. Cytoplasmic localization 
of MRTF-A was ignored due to melanin. We are presently planning on further 
analyzing more normal and SSc samples using a different color of MRTF-A 
staining, as limitations were found in distinguishing the two colors (hematoxylin: 
blue, MRTF-A: brown) used in the staining methods. These findings suggest that 
pathological MRTF-A activation may result from impairment of MRTF-A 
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regulatory mechanisms and may be partly responsible for phenotypic changes 
and promotion of fibroblast activation as seen in a recent study of the epidermis 
of SSc patients (Aden 2010).  
Surprisingly, areas typical for myofibroblasts showed little MRTF-A 
labeling. Prominent staining is also shown in endothelial, perivascular and some 
perivascular inflammatory cells of SSc patients. Perivascular staining was not 
seen in healthy controls. This suggests that further focus should include 
microvascular and inflammatory cells in addition to myofibroblasts. Since the 
extent and subset (localized vs. systemic) of the disease was not known in 
scleroderma samples, this suggests that sustained MRTF-A activation may play 
a role in the early pathogenesis of SSc as well as the perpetuation of the disease 
and myofibroblast differentiation. 
The presence of an ECM is an important aspect of the cellular 
environment, affecting growth, adhesion, differentiation, morphology and cell 
signaling in multiple cell lineages. A recent study on HDF cultures has indicated 
that an increase in matrix stiffness may induce excessive cell proliferation which, 
together with the lack of apoptosis, could contribute to the excessive cellularity 
and contraction during hypertrophic scarring (Hadjipanayi2009). As scleroderma 
begins with lesions of the skin, collagen synthesis and secretion was compared 
between HDFs and IMR90 fibroblasts. A study comparing the two cell lines 
grown in collagen matrices has shown HDF collagen fibers to be aligned 
perpendicular to interstitial fluid flow to a greater extent than IMR90 fibroblasts 
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(Ng 2006). The presence of aligned collagen fibers in vascular walls serves as a 
signaling factor for platelet activation, which is clinically significant in wound 
healing dysregulation (Ruggeri 2002). In both instances of our study, baseline 
collagen synthesis and secretion is greater in untreated HDFs supplemented with 
ascorbate. Furthermore, collagen secretion was up-regulated in both cell lines 
upon treatment with TGF-β which did not reach significance. These results 
indicate that HDFs may be more susceptible to fibrotic proliferation and scarring 
upon continuous ECM stimulation. However, this may be the result of the 
differences between the primary sources of the cell lines, as IMR90 cells are 
derived from female fetal lung fibroblasts at 16-weeks gestation, whereas HDFs 
are derived from neonatal male foreskin. 
MRTF-A translocates into the nucleus following sequential serum 
stimulation and Rho activation and subsequent SRF activation in fibroblasts 
(Miralles 2003). Recent work in our lab has focused on the nuclear 
translocalization of MRTF-A upon TGF-β activation. To further determine the 
influence on TGF-β on this response in HDFs, nuclear and cytoplasmic extracts 
of HDF samples were obtained at various time intervals. Our results indicate that 
collagen synthesis and secretion is enhanced in HDFs untreated and treated with 
TGF-β when compared to IMR90 fibroblasts. Furthermore, we have 
demonstrated that MRTF-A responds to changing media and to TGF-β in HDFs. 
Recent work in our lab has shown TGF-β stimulates translocation of MRTF-A to 
the nucleus in SSc lung fibroblasts after 8 hours in comparison to healthy 
54 
 
controls (data not shown). This may suggest that TGF-β may prolong nuclear 
translocation of MRTF-A in HDFs. Moreover, recent data suggests actin 
polymerization and SRF may mediate peripheral diurnal rhythms, linking them 
with central circadian clock oscillators of the hypothalamus (Zhao 2013). G-
actin:F-actin ratios in mouse liver cells oscillate over time in tandem with a 
circadian nuclear expression of MRTF-B; a high G:F ratio observed at 8 hours, 
indicating cytoplasmic localization (Gerber 2013). This may be indicative of the 
cytoplasmic accumulation of MRTF-A in HDFs at 8 hours post-treatment. 
MRTF-A regulates myofibroblast activation and fibrosis. Mice with a loss-
of-function mutation lack myoepithelial cells and are resistant to cardiac 
hypertrophy (Li 2006). Genetic deletion of MRTF-A in mice has been 
demonstrated to result in reduced cardiac fibrosis and COL1A2 expression 
following ANGII treatment (Small 2010). ANG II has been shown to induce TGF-β 
production in cardiac fibroblasts (Rosenkranz 2004). In this study COL1A2 
transcription was quantified by GFP fluorescence using a common threshold 
when treated with TGF-β and ANG II. Combination treatment with ANG II and 
TGF-β has previously been shown to be more effective in inducing collagen 
synthesis than ANG II alone but not more effective than TGF-β alone (S. Chen 
2005). Collagen transcription in response to TGF-β and ANG II is disrupted by a 
loss of function mutation of the MRTF-A gene in murine lung fibroblasts (Figure 
8). SB431542 attenuated collagen transcription in both WT and KO fibroblasts 
regardless of ANG II or TGF-β treatment. ANG II has been shown to activate a 
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molecular cascade in rat mesangial cells, stimulating the production and 
autocrine secretion of active TGF-β which in turn stimulates synthesis and 
accumulation of ECM components (Kagami 2004).SB431542 blocks the kinase 
activity of the TβR1, arresting the transmission of TGF-β signal and thus ANG II-
induced TGF-β signaling. Baseline collagen synthesis was attenuated in both WT 
and KO fibroblasts treated with SB431542, indicating a nascent production of 
TGF-β receptor ligands by the cell cultures. This also indicates that receptor 
function is independent of MRTF-A. However, ANG II did not significantly up-
regulate collagen transcription in WT mouse lung fibroblasts (Figure 9A), which is 
inconsistent with other research measuring ANG II-induced collagen synthesis in 
mouse podocytes (S. Chen 2005). This may indicate that ANG II may not 
enhance TGF-β production and thus collagen production in murine lung 
fibroblasts as previously thought. Further investigation is required, preferably with 
murine dermal fibroblasts, as this may be a more appropriate cell line for our 
studies with SSc skin. Total percentage of fluorescent KO cells were consistently 
lower in comparison to WT cells, but said percentages remained relatively the 
same regardless of inhibitor treatment (Figure 9B). Collagen secretion was 
analyzed by the Sircol Method, which indicated no significant changes, which is 
inconsistent with previous work in our lab  (Luchsinger 2011). This may be 
explained as Sircol assay measures secretion of all types of collagen. 
In conclusion, the activation of MRTF-A is an important aspect in collagen 
synthesis and regulation and may potentially serve as a therapeutic target for 
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future treatments of fibrotic disease such as SSc. Taken together, these studies 
indicate that excess collagen synthesis and extracellular matrix (ECM) 
component deposition, such as TGF-β, may further potentiate MRTF-A activation 
and dysregulation in the skin of SSc patients.  
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